palmitoleic acid poa c16:1 n7 omega7 monounsaturated fatty acid plant fish oil1 two isomer i.e cispoa cpoa transpoa tpoa different space structure fig 1. cpoa common natural poa widely report affect favorably glucose lipid metabolism multiple mechanisms2,3 cpoa observe affect key enzyme blood glucose metabolism regulate insulin secretion reduce insulin resistance4,5 orally administer cpoa induce satiety enhance release satiety hormone decrease food intake mice6 well reduce body weight ameliorate development hypertriglyceridemia hyperglycemia improve insulin sensitivity7 side transfatty acid subject ongoing discussion suggest positive negative association cardiovascular metabolic risk factors8 higher tpoa proportion plasma phospholipid improve insulin sensitivity decrease onset type 2 diabetes disease9 tpoa regulate glycolipid metabolism closely relate low density lipoprotein10,11,12 use biomarker reduce risk coronary heart disease type 2 diabetes study analyse fatty acid use gcfid gcms13 fatty acid sample use process require separation methylation measurement may destroy original molecular structure fatty acid biological matrix require big biological sample size amount methods14,15 previous study cpoa determine subcutaneous fat human body tpoa determine 200 08l plasma human gc thorough aminopropyl spe column separation isolute biotage transmethylated methanolichcl fatty acid methyl ester fame16,17,18 method available determine cpoa tpoa time important develop method simultaneous determination cpoa tpoa biological sample explore biological activity drug delivery system regenerative medicine present paper quantification method use uplcmsms determine cpoa tpoa simultaneously rat serum develop prove selective sensitive wide range detection low limit detection could use ascertain pharmacokinetics cpoa tpoa cpoa tpoa purchase nuchek 99 elysian usa hplcgrade formic acid obtain roe scientific inc. powell oh usa hplcgrade acetonitrile methanol mtbe methyl tertbutyl ether obtain merck kgaa darmstadt germany ultrapure water millipore milliq system millipore corp. billerica usa solvent reagent commercially available reagent grade use rat approve experimental animal ethic committee nanjing university traditional chinese medicine accordance nih guideline ethical approval number 201811a027 author comply arrive guideline 18 male spraguedawley rat weigh 280 ± 20 g maintain 12 h:12 h lightdark cycle temperaturecontrolled room throughout study standard rat chow tap water supply ad libitum rat serum collect vein rat narcotize intraperitoneal injection pentobarbital sodium produlab pharma b.v. 40 mgkg analyte separation perform agilent uplc1290 system agilent corp. milford usa use bd c18 column 2.1 × 100 mm 2.1 μm thermo fisher scientific usa mobile phase include water acetonitrile b b 20:80 vv flow rate 0.3 mlmin injection volume 1 μl identification cpoa tpoa serum sample conduct use ab 5500 qtrap uplcmsms ab sciex framingham usa equip electro spray ionization esi quantitative analysis cpoa tpoa also perform uplcmsms detection perform negative ion mode follow condition curtain gas 35.0 lh ion source gas 50 lh ab analyst 1.6.0 software ab sciex framingham usa use system control data acquisition esimsms parameter show table 1. detection perform negative ion mode condition cpoa tpoa detection optimize use standard product ion obtain deprotonated molecular ion cpoa tpoa include three main ion compound mz 235.2 126.9 111.0 mz 234.7 127 111.1 respectively individual standard stock solution cpoa tpoa 2.50 mgml 2.24 mgml respectively prepare acetonitrile stock solution serially dilute acetonitrile provide standard work solution concentration range 0.17542.0 μgml cpoa tpoa solution store 20 °c bring room temperature use calibration standard c curve prepare spike 20 μl appropriate analyst work solution 50 μl blank rat serum effective concentration 0.1 0.5 2.5 5 10 12 μgml cpoa tpoa qc sample prepare compound sample concentration 0.5 μgml cpoa tpoa store 20 °c use rat serum sample serve qcs process follow sample procedure unknown sample 50 μl serum sample blank pharmacokinetics serum sample 2.0 ml centrifuge tube 60 μl aqueous solution formic acid 5 100 μl methanol 1250 μl mtbe add mix vortexing 3 min centrifugation 18,000×g 10 min clear supernatant 1 ml extract new centrifuge tube blow flow nitrogen redissolved 200 μl acetonitrile solution centrifugation 18,000×g 10 min supernatant inject uplcmsms system assay validation perform base currently accept fda prescription per guideline international conference harmonization technical requirement registration pharmaceutical human use blank serum sample process extraction procedure test ensure rat serum interference analyte serum sample preparation 60 μl aqueous solution formic acid 5 100 μl methanol 1250 μl mtbe add mix vortexing 3 min centrifugation 18,000×g 10 min clear supernatant 1 ml extract new centrifuge tube blow flow nitrogen redissolved 200 μl acetonitrile solution determination extraction recovery cpoa tpoa three qc concentration calculation recovery compare analyte peak area ratio analyte serum sample analytes serum matrix extract analytefree serum sample prior chromatography extract rat serum matrix effect endogenous substance present might cause ion signal suppression enhancement matrix effect three qc concentration 0.5 2.5 10 ngml measure compare peak response sample postextraction pure standard solution contain equivalent amount two compound b. ratio ab × 100 use evaluate matrix effect extraction recovery matrix effect cpoa tpoa evaluate simultaneously method sample storage process procedure stability cpoa tpoa rat serum assess analyze replicate n 6 three qc concentration freezethaw stability determine three freezethaw cycle stability test qc sample determine accord calibration curve freshly prepare standard male rat spraguedawley 280 ± 20 g obtain laboratory animal center nanjing university chinese medicine nanjing china animal handle procedure follow standard operate procedure approve institutional animal care use committee rat dose follow overnight fast except water ad libitum pharmacokinetic study 18 male rat randomly divide three group first group rat give volume solvent saline intragastrically blood sample collect time point 0 10 20 30 40 60 min 2 h 3 h 6 h 12 h 24 h. rat second group administer i.g cpoa 75 mgkg body weight serial blood sample collect tube via orbital venous plexus time point 0 10 20 30 40 60 min 2 h 3 h 6 h 12 h 24 h administration third group rat administer intragastric gavage tpoa 75 mgkg body weight blood sample collect time point 0 10 20 30 40 60 min 2 h 3 h 6 h 12 h 24 h. serum separate store freeze 80 °c analysis follow main pharmacokinetic parameter analyze use noncompartmental pharmacokinetics data analysis software pk solution 2 tm summit research service montrose co usa area curve zero last measurable serum concentration point auc 24 h maximum concentration cmax timetomaximum concentration